
ACXP Stock Forecast & Price Target
ACXP Analyst Ratings
Bulls say
Acurx Pharmaceuticals Inc. has received encouraging feedback from the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), which has positioned the company favorably for its upcoming Phase 3 trial in adult populations. The notable antimicrobial activity and established favorable safety profile observed in patients amplify the potential for successful clinical outcomes. Additionally, the positive opinion on the company's Pediatric Investigation Plan (PIP) for the use of IBZ in children further enhances the growth prospects and market potential of Acurx's developing therapies.
Bears say
Acurx Pharmaceuticals Inc. faces significant financial hurdles due to its clinical stage status, which limits immediate revenue generation and increases the reliance on external funding to support ongoing research and development efforts. The company's focus on a niche segment of antibiotic development may heighten investor skepticism, as the competitive landscape in the biopharmaceutical industry is characterized by high failure rates and substantial regulatory challenges. Furthermore, persistent valuation concerns, compounded by operational risks and the potential for delayed product timelines, contribute to a negative outlook on the company's long-term financial viability.
This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.
ACXP Analyst Forecast & Price Prediction
Start investing in ACXP
Order type
Buy in
Order amount
Est. shares
0 shares